{"name":"Marlise Luskin, MD","slug":"marlise-luskin-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ABL001","genericName":"ABL001","slug":"abl001","indication":"Chronic myeloid leukemia (CML) with BCR-ABL mutations resistant to standard tyrosine kinase inhibitors","status":"phase_3"}]}],"pipeline":[{"name":"ABL001","genericName":"ABL001","slug":"abl001","phase":"phase_3","mechanism":"ABL001 is an allosteric inhibitor of BCR-ABL that binds to a pocket distinct from the ATP-binding site, allowing it to overcome certain resistance mutations.","indications":["Chronic myeloid leukemia (CML) with BCR-ABL mutations resistant to standard tyrosine kinase inhibitors"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1rQ0poUDg1VFBVWmJEcEUtYVhFVXRQSnlzZzJIT1I3SnNSaDRLTW1XTmo0ZGdVX0tFNlU3bm9RUHRSdEcydTkwZUlld2RtaWV2eHBhajNuNGY0b05JOFF6QjlMWmxvZm5oZktUcmFiM1hfYy1mRkVKekh6dw?oc=5","date":"2024-08-02","type":"pipeline","source":"Wiley","summary":"Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions - Wiley","headline":"Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxORUUyMzZCZVNNaFVHVDRTa1ZFcGtsZW9leTVla2hveDVkWHpuQ0RCLUh6MXJwTXpXWFN4STJtSFpiR1FZYmd6RHlrVWxTMElfZjhNQ3hBUHVjeERwT2pRRWt4TkFfUGxSalpVRngza2N5MWt5X18yM3A2Skp6UDZkTE9IZXQ4Qjc3QW4ydHJuZ1dySU0tSnlPUlNLeVZTYTh0TkIzclcyWUN2VHlBOG1VYVJQUXVWWnF5OWFBVXVLaWQyS183c3BtdmJIVEtKdDg?oc=5","date":"2023-07-11","type":"pipeline","source":"Healio","summary":"Overweight, obesity linked to adverse outcomes among AYAs treated for leukemia - Healio","headline":"Overweight, obesity linked to adverse outcomes among AYAs treated for leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPQUlWMnBncl96S3dHY0psUEhUMVZVUmtRc05MZVhSMXRxcmZQTERHRnhYS1lFQ1dJSlF6Rm5FUURDeEZoNjRMT2g0WVl5Mzg3ZzFzVmkxdmJWZlZWdG83b2k4V0FjS3Y4NEszbnkzdXk4UTR4R1JvQzFOX0VaMEJrd1dNWVRRUE1MRFU3VnlITER1VWU3RUV0T0VDUmhIUC1QeFl3dzV3RU5fbU05M3RPSF9lMnBwZzRJUi1zdXIyUW1yTHBXQ3U3MWhzUW8?oc=5","date":"2023-02-16","type":"pipeline","source":"Healio","summary":"Ponatinib ‘should be considered a standard of care’ for newly diagnosed Ph+ALL - Healio","headline":"Ponatinib ‘should be considered a standard of care’ for newly diagnosed Ph+ALL","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}